Keywords: Genzyme, Sanofi-Aventis, M&A, Rejects tender offer

Genzyme board unanimously rejects Sanofi-Aventis’ $69/share tender offer as “inadequate and opportunistic”

Article | 08 October 2010

Print This

Giving its official reaction to French drug major Sanofi-Aventis’ (Euronext: SAN) move to approach shareholders directly (The Pharma Letter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in